MacroGenics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. The unaudited results cover a clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics and commercializing MARGENZA with a partner.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $26.0 million | $30.8 million | $37.1 million | $47.6 million |
| Operating loss | $41.8 million | $40.3 million | $108.4 million | $91.6 million |
| Net loss | $41.3 million | $39.9 million | $107.7 million | $91.2 million |
| Net loss per share | $0.67 | $0.66 | $1.76 | $1.56 |
| Cash used in operating activities | — | $106.9 million | $74.7 million |
Q2 revenue included $16.9 million from collaborative and other agreements, $4.7 million of product sales, $4.0 million of contract manufacturing, and $0.5 million from government agreements. For the first half, research and development expense was $113.2 million (up 4%); selling, general and administrative expense was $29.9 million (down 1%). The filing does not provide a clear consolidated gross-margin figure. Management said MARGENZA product costs were favorably affected because sold inventory had previously been expensed as research and development.
Balance sheet and liquidity
- At June 30, cash and cash equivalents were $21.5 million and marketable securities were $112.3 million, a combined $133.7 million. Cash and cash equivalents fell from $123.5 million at year-end 2021.
- Total current assets were $167.6 million versus current liabilities of $50.9 million. Total liabilities were $75.6 million, including lease liabilities; the filing reports no debt borrowings.
- Operating cash outflow was $106.9 million for the first half, compared with $74.7 million in 2021. Investing activities provided $4.6 million; financing activities provided $0.3 million.
- Management said cash, cash equivalents and marketable securities at June 30, together with a subsequent $30.0 million Incyte milestone, anticipated collaboration payments, product revenues and restructuring savings, should fund operations into 2024. A separate liquidity note says current resources are expected to fund operating plans for at least 12 months from filing. Both estimates depend on assumptions and execution.
Material changes and notable developments
- First-half revenue declined 22%, mainly reflecting $15.0 million less Incyte milestone revenue and lower Incyte commercial-supply revenue; higher MARGENZA sales, a $5.0 million Zai Lab milestone and new Incyte manufacturing revenue partly offset the decline.
- MARGENZA net sales rose 47% in Q2 to $4.7 million and 102% in the first half to $8.3 million.
- First-half R&D spending rose $4.3 million, including increased MGC018, discovery/preclinical and lorigerlimab costs. Lower spending on flotetuzumab, retifanlimab and margetuximab partly offset the increases.
- In January 2022, MacroGenics entered a three-year Incyte manufacturing agreement, received a $10.0 million upfront payment and recognized $4.0 million revenue in the first half. At June 30, $9.5 million was deferred under this agreement.
- In July 2022, after quarter-end, MacroGenics received $30.0 million in Incyte milestone payments following a further amendment to the retifanlimab agreement.
- In August 2022, after quarter-end, the company announced a workforce reduction of approximately 15% to prioritize lead assets. Expected savings, charges and operational effects were not quantified in the supplied filing text.
Outlook, risks and contingencies
- Management expects continued losses and substantial R&D needs; the company had an accumulated deficit of $1.1 billion at June 30. Its outlook depends on product revenues, collaborations, financing availability and restructuring savings.
- Clinical and regulatory outcomes remain uncertain. Incyte’s retifanlimab application for anal cancer received an FDA Complete Response Letter, and the European application was withdrawn. Zai Lab had discontinued tebotelimab development in the indications it was enrolling and was evaluating other plans.
- The MGD024 trial start remained on hold pending alignment with the FDA on its submission. In July 2022, the company announced discontinuation of an enoblituzumab combination trial in recurrent or metastatic head and neck cancer following an internal safety review. COVID-19-related enrollment delays, competition, manufacturing constraints and macroeconomic conditions could also affect operations.
- A securities class action related to the SOPHIA trial dismissal was on appeal. The company said the outcome was uncertain, could not estimate a loss range and recorded no liability.
- Available-for-sale securities had $0.3 million of unrealized losses at June 30, primarily attributed to interest-rate and market-spread changes; no credit-loss allowance was recorded.
Key facts for investors to verify
- Whether MARGENZA sales growth and collaboration/manufacturing revenue can offset lower or variable milestone receipts.
- Whether the stated runway into 2024 remains achievable, including the impact of the July Incyte payment, clinical spending and restructuring savings.
- Progress, safety and regulatory status of MGC018, lorigerlimab, MGD024 and other priority programs, and the effects of discontinued or paused trials.
- The implementation costs and realized savings from the August 2022 workforce reduction.
- Any material developments in the Incyte retifanlimab program and the securities-litigation appeal.